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ABSTRACT 
Alzheimer’s disease (AD) is a progressive, neurodegenerative disease that is 
characterized by progressive loss of memory and cognitive function. The causative 
factors of this disease include modifications in neuronal cell metabolism, such as the 
progression of neurotic injury by amyloid beta (Aβ), and tau tangle deposition in the 
brain. Recent studies show that brain atrophy and other pathologic conditions are 
responsible for dementia in older individuals (80 years of age or older). Non-
pharmacological interventions may have a role in both the prevention and slowing 
disease progression in AD. The role of exercise training in disease prevention has been 
evaluated in large epidemiological studies even though much less is known about the 
potential benefit of exercise training in patients already diagnosed with AD. Several 
studies in transgenic mouse models of AD suggest exercise training reduces soluble and 
insoluble Aβ levels in the brain. This study assessed the effectiveness of long-term 
exercise training (12-months) in an AD transgenic mouse model, Tg2576. Amyloid 
plaque levels and behavioral profile of mice were evaluated after 12 months of training. 
Mice that received daily exercise training demonstrated beneficial behavioral profile and 
reduced plaque counts in a dose-dependent manner. 
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INTRODUCTION 
 
Neurodegenerative Diseases 
Neurodegenerative diseases are characterized by selective and symmetric loss of 
neurons in motor, sensory, and cognitive systems (Gorman, 2008). Description of the 
patterns of cell loss and the identification of disease-specific cellular markers have aided 
in nosologic classification. Senile plaques, neurofibrillary tangles, neuronal loss, and 
acetylcholine deficiency define Alzheimer’s disease (AD), depletion of dopamine 
characterizes Parkinson's disease (PD), cellular inclusions and swollen motor axons are 
found in amyotrophic lateral sclerosis (ALS), and γ-aminobutyric acid containing 
neurons of the neostriatum are lost in Huntington's disease (HD) (Martin, 1999).  
In some neurological diseases such as AD, genes have been found which lead to a 
clinical and pathological syndrome, with only variations in the age at onset and the rate 
of progression. In other disorders such as Downs’s syndrome, errors in DNA replication 
resulting in an increased number of trinucleotide repeats are associated with selective 
patterns of neurodegeneration (Martin, 1999). In these disorders, heterozygotes are as 
severely affected as homozygotes, suggesting that the biochemical change caused by the 
mutation results in toxicity to the cell (Martin, 1999). In contrast, in autosomal recessive 
disorders such as Friedreich's ataxia, the manifestations of the disease are caused by a 
cellular loss of function due to the failure of protein production. These conditions are 
most likely caused by abnormalities in the transport, degradation, and aggregation of 
proteins that lead to cell-specific changes and ultimately to neuronal death, probably by 
apoptosis (Mattson, 2000; De Strooper, 2010). 
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The identification of specific genetic and environmental factors responsible for 
these diseases has strengthened evidence for a shared pathway of neuronal death, which 
involves oxidative stress, stressed calcium homeostasis, mitochondrial dysfunction and 
activation of cysteine proteases called caspases (Brady and Morfini, 2010). These 
cascades are counteracted by survival signals, which suppress oxygen radicals and 
stabilize calcium homeostasis and mitochondrial function. With the identification of 
mechanisms that either promote or prevent neuronal apoptosis, new approaches need to 
be developed for preventing and treating neurodegenerative disorders such as AD (Li et 
al., 2015). 
Overview of AD 
In 1901, Dr. Alois Alzheimer’s patient, Auguste Deter had strange behavioral 
symptoms such as short-term memory loss. In April 1906, after her death, Alzheimer 
along with two Italian physicians used Nissl staining techniques to identify amyloid 
plaques and neurofibrillary tangles in her brain. Later in November 1906, Dr. 
Alzheimer’s speech at the physicians’ conference in Germany about the pathology and 
clinical symptoms of pre-senile dementia was groundbreaking.  
AD usually begins in the seventh to ninth decade of life, but an early-onset 
familial form is now well recognized where disease symptoms are manifested in the fifth 
and sixth decades (Thorvaldsson et al., 2011). The disease affects over 4 million people 
in the United States, resulting in over 100,000 deaths per year. The risk of AD rises 
sharply with advancing age, and as life expectancy increases, the effect of the disease will 
also increase (Price et al., 2009).  
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Brain changes associated with AD lead to growing trouble with memory, thinking 
and reasoning, making judgments and decisions, planning and performing familiar tasks, 
vision loss, and changes in personality and behavior (Shankar et al., 2008). Symptoms of 
AD progressively deteriorate over time. In many instances, AD patients start developing 
symptoms earlier but only receive an official diagnosis years later. Post diagnosis patients 
enter the second stage of the disease where they develop mild cognitive impairment 
which will last two to ten years. Alzheimer’s dementia occurs during the final stages  
where there is severe damage and this is the most extreme form of the disease. The 
similarity of pathologic findings in the different AD groups provides evidence for a 
common pathophysiological pathway in AD (Lippa et al., 1996). With respect to the 
severity of changes and location of tangle-bearing neurons, the disease progresses in six 
stages: transentorhinal stages I–II: clinically silent cases; limbic stages III–IV: incipient 
AD; neocortical stages V–VI: fully developed AD (Sperling et al., 2011).  
Pathology of AD 
The neuropathological features of neurofibrillary tangles and senile plaques 
described by Dr. Alzheimer, in 1907, result in the progressive loss of memory and 
cognitive function (Harman, 2006). These modifications are indications of the cause of 
AD, especially neuronal cell metabolism in the form of neuritic injury, and neuronal cell 
death affecting the brain (Serrano-Pozo et al., 2011).  
Recent studies show that brain atrophy and other pathologic conditions are 
responsible for dementia in the oldest persons (80 years of age or older). AD may be 
primarily a disorder of synaptic failure where hippocampal synapses begin to decline in 
patients with mild cognitive impairment in whom residual synaptic outlines show  
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compensatory increases in size. As the disease progresses synapses are disproportionately 
fewer relative to neurons (Loo et al., 1993). The core symptoms of AD include cognitive 
impairment, decline in the ability to perform daily activities, and manifestation of 
behavioral and psychological symptoms of dementia (BPSD). 
There is progressive brain cell death that occurs over a course of time in AD and 
the total brain size shrinks, where the tissue has progressively fewer nerve cells and 
connections. While these cannot be observed in the brains of living people affected by 
AD, postmortem results show tiny inclusions in the nerve tissue called plaques. Cerebral 
plaques that are burdened with Aβ, dystrophic neuritis in neocortex, and neurofibrillary 
tangles in medial temporal-lobe structures are important pathological features of AD 
(Christen, 2000) (Figure 1).  
 
 
Figure 1. PET image comparison of normal versus AD brain. Positron Emission 
Tomography (PET) scan images of normal brain and AD brains with amyloid plaques 
(Credit: University of Pittsburgh, PET Amyloid Imaging Group). 
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Amyloid Cascade Hypothesis of AD 
  There currently exist several hypotheses concerning the development and 
progression of AD. The most studied and widely accepted is the amyloid cascade 
hypothesis. This hypothesis suggests that the deposition of a protein, the amyloid-beta 
(Aβ) peptide in the brain, is a crucial step that ultimately leads to AD (Saunders et al., 
1993; Lippa et al., 1996; Sperling et al., 2011).  The aggregation of Aβ into toxic 
oligomers and eventually plaque later in life is directly related to soluble Aβ peptide 
concentrations in the brain during midlife (Bero et al., 2011). Soluble Aβ concentration in 
the brain depend on the relative rates of which the peptide is produced and cleared. The 
aggregation of Aβ into oligomers and eventually plaque is shown in Figure 2.  
 
 
Figure 2. Plaque formation. Soluble Aβ aggregates into toxic soluble oligomers, then 
insoluble fibrils, and finally into plaque in the extracellular space in the brain (Image 
courtesy of the National Institute on Aging/National Institute of Health). 
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Aβ Production.  Aβ is produced when two different enzymes cleave the 771 
amino acid amyloid precursor protein (APP) which is crucial for neuronal development 
and synaptic connection (Mattson, 2000). The enzymes beta-secretase and gamma-
secretase sequentially cleave APP producing Aβ, which can be 38, 40 or 43 amino acids 
long (Fig 1) (Querfurth and LaFerla, 2006). The Aβ is 42 amino acid form is more 
hydrophobic than the shorter forms and is more likely to aggregate (Yang et al., 2003). 
The accumulation of Aβ in the brain leads to damage of neurons which in turn triggers 
inflammatory responses as the brain attempts to repair itself (Harman, 2006). 
The concept of Aβ-derived soluble toxic oligomers has been proposed to account 
for the neurotoxicity of the amyloid-β peptide. These intermediate forms lie between free, 
soluble Aβ monomers and insoluble amyloid fibrils (Zhang-Neus et al., 2006). Soluble 
Aβ oligomers are organized into different structures ranging from dimers (Walsh et al., 
2002) to dodecamers (Lesne et al., 2006) and include; trimers (Walsh et al., 2002; Glabe, 
2006), tetramers (Walsh et al., 2002; Glabe, 2006), pentamers and decamers (Ahmed et 
al., 2010), and Aβ-derived diffusible ligands (ADDLs) (Hepler et al., 2006, Lambert et 
al., 1998). Additionally, the role of different cleavage variants, Aβ1–40 and Aβ1–42, has 
been under investigation for some time. They are the two dominant Aβ peptides produced 
by β-secretase and γ-secretase. In vitro, Aβ1–40 tends to be more stable in isolation and 
remains in the monomer stage longer before it aggregates to form fibrils. Aβ1–42 tends to 
remain in a mix of monomer, trimer, and tetramer form until it aggregates into fibrils 
(Sengupta et al., 2016).  
Toxic, soluble Aβ species in different forms have been isolated from transgenic 
mouse brains and the human brain in vitro under various experimental conditions (Karran 
 7 
 
et al., 2011; Mattson, 2000; Oddo et al., 2003). Dodecamers appear to be diffuse 
throughout the tissue and exert toxic effects in cultures. Aβ oligomers contain mainly 
replicates of Aβ trimers and were identified in the brains of Tg2576 mice (Lesne et al., 
2006). This soluble aggregate of Aβ appears to impair memory function in these animals, 
irrespective of neuronal loss and leads to synaptic dysfunction in humans (Lesne et al., 
2006). Consistent with its toxic effects, these Aβ oligomers were also found to correlate 
with markers of synaptic dysfunction and levels of hyperphosphorylated tau (Sengupta et 
al., 2016). This suggests that toxicity is dependent on the size, aggregation state, and 
diffusion of Aβ oligomers. 
 
 
Figure 3. Processing of Amyloid Precursor Protein. In Panel A, α-secretase cleaves the 
amyloid precursor protein (APP) initiating the nonamyloidogenic processing. sAPPα and 
a carboxy-terminal fragment, C83 is then produced and C83 is further digested by γ 
secretase, liberating the amyloid intracellular domain (AICD). β-secretase beta-site 
amyloid precursor protein cleaving enzyme 1 (BACE-1), cleaves APP releasing sAPPβ 
and C99, initiating the amyloidogenic processing. Further C99 is digested by γ secretase 
releasing Aβ. Reproduced with permission from (Querfurth and LaFerla, 2006), 
Copyright Massachusetts Medical Society. 
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Aβ Clearance. Aβ clearance from the brain occurs through enzymatic and non-
enzymatic pathways. Non-enzymatic pathways include 1) the bulk flow of the interstitial 
fluid (ISF) into the CSF by ISF drainage pathway through perivascular basement 
membranes, (Cserr, 1983; Hladky and Barrand, 2014; Bedussi et al., 2015) 2) the uptake 
by microglial or astrocytic phagocytosis (Jones et al., 2013; Fu et al., 2014), and 3) the 
transport across the blood brain barrier mediated by clearance receptors such as low-
density lipoprotein receptor-related protein 1 (LRP1) (Jones and Shusta, 2007; Storck et 
al., 2016; Fiala et al., 1998), very low-density lipoprotein receptor (VLDLR) (Holtzman 
et al., 2012; Deane et al., 2009) and P-glycoprotein localized predominantly on the 
abluminal side of the cerebral endothelium (Terasaki and Ohtsuki, 2005; Cornford and 
Hyman, 2005).  
Enzymatic clearance pathways include the Aβ-degrading enzymes neprilysin 
(Yoon and Jo, 2012; Baranello et al., 2015; Hafez et al., 2011), insulin-degrading enzyme 
(IDE) (Duckworth et al., 1998; Bates et al., 2009), and matrix metalloproteinase-9 
(MMP9) (Miners et al., 2008; Yoon and Jo, 2012). 
Aβ is trafficked via the interstitial fluid (ISF) into the CSF via bulk flow; 
however, this has been shown to be a minor route for Aβ clearance in mice, as it only 
accounts for approximately 10% of Aβ clearance (Fagan et al., 2009). Microglia, the 
brain's local macrophages, play an essential role in Aβ clearance through their ability to 
take up and degrade soluble and fibrillar forms of Aβ (Rogers et al., 2002; Lee and 
Landreth, 2010; Jiang et al., 2008). Both microglia and astrocytes secrete proteinases, 
including IDE, that mediate the degradation of Aβ peptides in the extracellular 
environment (Butovsky et al., 2007). Microglial cells have neuroprotective actions by 
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producing neurotrophic factors and by eliminating Aβ from the brain by phagocytosis 
before formation of senile plaques (Kurochkin and Groto, 1994; Simard and Rivest, 
2006; Harry and Kraft, 2008).    
The other route for Aβ clearance is direct trafficking out of the brain via the 
blood–brain barrier (BBB) into peripheral circulation (Shaw et al., 2009). Astrocytes, a 
component of BBB plays a role in plaque maintenance and Aβ clearance (Lee and 
Landreth, 2010; Kraft et al., 2013). Animal experiments demonstrated that astrocytes 
internalize Aβ by receptors such as LRP1, which has a function to transcytose ligands 
across the BBB. LRP1 also has the capability to uptake Aβ bound to apolipoprotein 
(Zhao et al., 2009). Aβ1-40 is cleared rapidly across the BBB via LRP1 while Aβ1-42 is 
removed across the BBB at a slower rate (Thal, 2012; Deane et al., 2009; Storck et al., 
2016). 
 The brain contains vigorous essential Aβ clearance mechanisms (Tanzi et al., 
2004). Aβ peptides are proteolytically degraded within the brain principally by neprilysin 
(Iwata et al., 2004; Baranello et al., 2015; Hafez et al., 2011) and IDE (Kurochkin and 
Goto, 1994; Duckworth et al., 1998; Bates et al., 2009). Administration of inhibitors of 
these proteinases into the brain results in substantial elevation of Aβ levels in the brain 
and stimulation of plaque deposition (Dolev et al., 2004). On the other hand, 
overexpression of neprilysin or IDE lowered brain Aβ levels and reduced plaque 
formation (Lehman et al., 2003). It has been argued that the principal approach of Aβ42 
clearance from the brain is through its proteolytic degradation because this peptide is not 
efficiently transferred through the vasculature (Jiang et al., 2008).  
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Other Hypotheses of AD 
While the amyloid cascade hypothesis is currently the most widely accepted 
hypothesis of AD, other hypotheses have been proposed. These hypotheses tend to 
incorporate the development of plaques that are found between the dying cells in the 
brain; from the build-up of a protein, Aβ (Harman, 2006; Fulda et al., 2010), neuritic 
plaques (NPs) (Serrano-Pozo et al., 2011; Li et al., 2016), tau protein dysfunction 
(Mondragon-Rodriguez et al., 2014), and intracellular neurofibrillary tangles (NFTs) (De 
Strooper, 2010). 
Studies on the correlation of NFTs and NPs to cognitive deterioration in AD have 
yielded differing results (Nelson et al., 2007). For this reason, NFTs and NPs may 
contribute only slightly to dementia, or NFTs and NPs are less relevant to cognitive 
decline in older patients with AD than other pathologic processes (De Strooper, 2010; 
Nelson et al., 2007). A study quantitatively assessing the numbers of intracellular and 
extracellular NFTs in AD brains and of controls, found that in some cases, NFTs were 
not removed from the brain throughout the disease process (Mattson, 2000). This finding 
provides evidence that the protein constituent of NFT is resistant to proteolytic removal 
due to extensive cross-links. Additionally, correlation between the number of NFTs and 
neuronal loss indicates there are at least two distinct mechanisms responsible for neuronal 
death in AD that is related to the presence of neurofibrillary pathology (Yang et al., 
2003). 
  Another proposed pathological component of AD, paired helical filaments of tau 
are formed first in the intracellular space of the neuron, and coalesce to form NFTs in the 
soma and axonal processes. At the same time or a little later, precursor proteins (either in  
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the dimeric or higher aggregated forms) are deposited in the extracellular space 
associated with the pre-synaptic axonal processes. These deposited proteins form the 
amyloid fibrils which may either crystallize within the center of a plaque, or the fibrils or 
their precursor subunits may migrate and accumulate around and within the walls of 
small blood vessels (De Strooper, 2010). 
Aβ aggregation and deposition triggers a process that leads to neuronal loss via 
the formation of paired helical filaments of tau (Saido et al., 1995,1996; Fagan et al., 
2009). Nonetheless, it remains to be clarified how deposited Aβ triggers or accelerates 
tau pathology and how tau pathology ultimately leads to neuronal loss (Fiala et al., 2007). 
However, a recent study demonstrated that the formation of intracellular amyloid-like 
fibrils resulted in the seizing of key intracellular proteins, which then led to the imbalance 
of essential cellular processes (Mucke and Selkoe, 2012). It is possible that intracellular 
tau aggregates act in a similar fashion (Glabe, 2006). Tau pathology follows a regular 
neurological path that correlates with the observed sequence of cognitive defects. Tau 
pathology also correlates with neuronal loss and cerebral atrophy, which in turn 
correlates with dementia. In addition, preclinical evidence suggests that in the absence of 
plaques, tau pathology can spread throughout the brain (Hardy, 2005). 
In summary, Aβ aggregation and deposition is a very early event that can trigger 
tau pathology and will do so in many individuals, but the deposition of Aβ does not 
correlate with the presence of neurofibrillary tangles, cell loss or dementia. Given the 
current knowledge discussed above, and recognizing that there are considerable gaps in 
our understanding of AD pathology, one hypothesis that accommodates most of the 
known data is that Aβ aggregation and deposition triggers a process that leads to neuronal 
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loss. Nonetheless, it remains to be clarified how deposited Aβ ultimately leads to 
neuronal loss.  
 
Genetic Aspects of AD 
  Early studies in familial AD (FAD) identified a locus on the long arm of 
chromosome 21, the region known to be duplicated in Down's syndrome, that encodes for 
APP. Subsequently, seven different mutations in the same gene have been found, all of 
which increase the production of Aβ 1–43 leading to fibrillar aggregation toxic to 
neurons (Shen and Kelleher, 2007).  
  Autosomal dominant mutations that cause early onset familial AD (eFAD) occur 
in three genes: presenilin 1 (PSEN1), presenilin 2 (PSEN2), and APP (Mattson, 2000). 
PSEN1 and PSEN2, are homologous proteins that can form the catalytic active site of 
gamma-secretase. Also apolipoprotein E (APOE) gene represents the major genetic risk 
factor for AD (Pastor et al., 2003). Humans contain three common APOE alleles: 
APOE2, APOE3 and APOE4. The APOE4 allele is responsible for the age of disease 
onset, APOE3 is neutral, and APOE2 may be protective (Dal Forno et al., 2002; Karran et 
al., 2011). Compared to individuals lacking APOE4 alleles, the risk for people who 
possessed one APOE4 allele were at a 2-3-fold increase while individuals with two 
APOE4 alleles were at a 12-fold increase in AD onset (Kim et al., 2009). A series of 
experiments in some APP transgenic mice that had the human APOE genes indicate that 
these associated proteins facilitate the clearance of amyloid-β, with APOE3 and APOE4 
being increasingly less effective at clearing Aβ (Allan and Ebmeier, 2011; Karran et al., 
2011).  
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  Other AD risk factor genes are being discovered via genome-wide association 
(GWA) studies. Of interest, the genes that cause the autosomal dominant form of the 
disease have not been detected as risk factors in the GWA studies that have been 
conducted so far (Van Broeckhoven and Kumar-Singh, 2006). The most likely 
explanation for this is that the common genetic variation around these three genes is 
simply not sufficient to alter their expression in a way that increases the risk of AD 
(Jones et al., 2010). 
  The amyloid cascade hypothesis appears to explain and incorporate several key 
points that are relevant to the disease process, including the pathology, the phenotypes 
mediated by the genes that cause autosomal dominant disease, and the genetic risk caused 
by the APOE gene (Morris et al., 2010). However, this hypothesis does not consider the 
interaction of Aβ with tau. This was clarified, to some degree, by the discovery that 
mutations in the tau gene could cause dementia in the frontal lobe. Thus, tau pathology 
itself can cause neuronal loss. This observation places tau pathology downstream of Aβ 
pathology (Dal Forno et al., 2002). 
For the FAD-linked APP gene mutations, there are potential effects that pre-
dispose individuals to early onset AD. If the amount of Aβ42 is increased sufficiently, 
then early onset AD can result. For the amyloid-β C-terminal APP mutations, the increase 
in the Aβ42/Aβ40 ratio is sufficient to cause early onset AD (Querfurth and LaFerla, 
2006). For the presenilin mutations, the increase in the ratio of longer Aβ42 or Aβ43  
versus shorter Aβ40 or Aβ38 species, even in the framework of an overall reduction in 
amyloid-β production, is sufficient to cause early onset AD (Winkler et al., 2012). A 
recent study confirmed that Aβ43 is at least as pathogenic as Aβ42, and studies in 
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patients demonstrated that the ratio of Aβ peptides in the CSF of carriers of the presenilin 
1 mutation was substantially different from control patients and patients with sporadic 
AD (SAD) (Lippa et al., 1996). 
  Increases in the Aβ42/Aβ40 ratio or increases in the levels of Aβ42 or Aβ43 in the 
brain will cause individuals to develop AD (Bernstein et al., 2009; Lee and Han, 2013). 
However, the duration of the disease appears to be unchanged by genetic factors. This 
implies that changes in the amount of Aβ or Aβ ratios are not important modifiers of the 
disease process (Pike et al., 1993; Glabe, 2006). The reduction in Aβ42 levels in the CSF 
is an early event in the disease process (Fagan et al., 2006, 2009) but there are very few 
studies demonstrating that once Aβ deposition has occurred, the amount of deposition can 
be correlated with neuronal loss, paired helical filaments of tau or dementia. 
 
Therapeutic Strategies 
  It is always preferable to treat any disease as early as possible. If the trigger event 
is the onset of Aβ deposition, then testing the amyloid cascade hypothesis would require 
a clinical trial in cohorts with normal scans of people who are at risk of developing AD 
(De Meyer et al., 2010). This represents a huge clinical challenge, including the selection 
of the clinical trial population and ethical considerations (Karran et al., 2011).  
  An effective treatment for SAD depends on the interpretation of the disease 
pathways. Prospective studies show that cognitive leisure activity and training can lower 
the risk of dementia (Verghese et al., 2003). Findings from these studies provide support 
for the concept of building a cognitive backup. Epidemiological studies suggest that 
simple lifestyle changes may be adequate to slow the onset and progression of AD (Pope, 
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2003; Beckett et al., 2015; Scarmeas et al., 2009; Buchman et al., 2012; Scarmeas et al., 
2011; Larson et al., 2006; Lindsay et al., 2002; Podewils et al., 2005; Abbott et al., 2004; 
Yoshitake et al., 1995; Ravaglia et al., 2008). 
  There are several strategies that are being developed to identify risk factors for the 
development of AD. Plasma cortisol levels, a widely used physiological marker of the 
stress state, have been correlated with the progression of AD (Dong and Csernansky, 
2010; Csernansky et al., 2006).  There have been reports of chronic isolation stress which 
leads to accelerated plaque development in certain mouse models of AD (Dong et al., 
2008; Rothman and Mattson, 2010; Hebda-Bauer et al., 2013; Cordner and Tamashiro, 
2016). Exercise training reduces oxidative stress and improves neuron regulation which 
counteracts damages from stress and age related neuronal degeneration (Kiraly and 
Kiraly, 2005; Cho and Roh, 2016). Friedland et al. (2001) validated that patients with AD 
were less active, both intellectually and physically, in midlife and that sedentariness was 
associated with a 150% increased risk of developing AD (Friedland et al., 2001). 
Similarly, Laurin et al. (2001), also demonstrated that physical activity was protective 
against the development of cognitive impairment (Laurin et al., 2001). Exercise training 
may be a major protective factor but without clinical guidelines, its prescription and 
success with treatment adherence remain elusive (Kiraly and Kiraly, 2005). The 
remainder of this review will focus on physical activity and exercise training as a 
preventative measure against the development of chronic disease in general and AD 
specifically. 
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Physical Activity and Disease 
  Physical activity has been shown to elicit positive effects in the prevention and 
delay of chronic diseases such as cardiovascular disease, depression, diabetes, and breast 
cancer (Morris et al., 1973; Dunn and Dishman, 1991; Knowler et al., 2002; Friedenreich 
and Cust, 2008). The most universally studied of the above-mentioned diseases is 
cardiovascular disease, and the role that physical activity plays in it has been well-
defined. Extensive study into neurological diseases has provided evidence indicating that 
the risk factors for cardiovascular disease overlaps with AD (Kesaniemi et al., 2001). 
Several epidemiological studies have shown that the switch from a sedentary to a 
physically active lifestyle reduces AD risk in humans (Fletcher et al., 1996; McGough et 
al., 2011; Vreugdenhil et al., 2012).  
  Physical Activity and Exercise Training. According to Casperson et al. (1985), 
physical activity could be divided into categories that are mutually exclusive of each 
other. Physical activity can be divided into light, moderate, or moderate intensity; those 
that are willful or compulsory; or those that are weekday or weekend activities. These are 
adequate ways of subdividing physical activity and the only condition is that the 
subdivisions be mutually exclusive and that they sum to the total caloric expenditure due 
to physical activity which may relate to a specific aspect of health (Casperson et al., 
1985). For example, physical activity of high intensity in a structured, planned, and 
repetitive manner could result in an exercise training effect leading to an improved 
physical fitness state, and better health. Existing work in the field of exercise physiology 
suggests that normal daily physical activity (light physical activity) alone does not reduce 
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the risk of diseases but an exercise training strategy typically results in a state of 
increased physical fitness (Haskell, 1994). 
Physical Activity in AD. It is becoming apparent that several risk factors for 
cardiovascular disease are also risk factors for neurodegenerative diseases including AD. 
Lower motivation of AD patients to exercise training regimens could be an obstacle for 
clinical studies, although this can be overcome, at least in part, by experimental studies 
(Selkoe and Schenk, 2003). Wilson and his group reported that physical activity for only 
several hours a week was associated with the risk of development of AD in small 
populations (Wilson et al., 2002). Epidemiological studies show that midlife physical 
activity was associated with delayed AD onset (Fratiglioni et al., 2004; Coltman and 
Berchtold, 2002; Andel et al., 2008). Physical activity improved cognition in adults with 
AD and those with cognitive impairment and dementia (Heyn, 2004; Smith et al., 2014; 
Etneir et al., 2006; Colcombe and Kramer, 2003; Brown et al., 2013). Also, intervention 
studies suggest that physical activity may have an impact in reducing AD risk although 
volume and intensity of exercise training have not been defined. 
Physical Activity and AD Transgenic Mouse Models 
  Because human epidemiology investigations are limited in their ability to study 
mechanisms related to AD, investigators have developed transgenic mouse models of the 
disease to use in this area of research. These studies, summarized in Table 1, have 
investigated physiological mechanisms underlying the effects of physical activity and 
exercise training on delaying the onset and slowing the progression of the disease 
process. 
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Table 1: Physical activity paradigms used in AD transgenic mouse models 
Study Mode Intensity Duration Frequency Length 
Adlard et al 
2005 
Wheel 
Running 
3-7-6.0 
m/min 
12 hr/day 7 days/week 5 months 
Wolf et al  
2006 
Wheel 
Running 
Not 
reported 
12 hr/day 7 days/week 8.5 months 
Cracchiolo et 
al 2007 
Wheel 
Running 
Not 
reported 
12 hr/day 7 days/week 3 months 
Nichol et al 
2007 
Wheel 
Running 
2.4 m/min 12 hr/day 7 days/week 2 months 
Parachikova 
et al 2008 
Wheel 
Running 
Not 
reported 
12 hr/day 7 days/week 3 weeks 
Richter et al 
2008 
Wheel 
Running 
2.0 m/min 12 hr/day 7 days/week 10 weeks 
Um et al 
2008 
Treadmill 
Running 
13.2 m/min 60 min/day 5 days/week 16 weeks 
Cho et al 
2010 
Treadmill 
Running 
13.2 m/min 60 min/day 5 days/week 16 weeks 
Cho et al 
2015 
Treadmill 
Running 
10 m/min 60 min/day 5 days/week 5 weeks 
Um et al 
2011 
Treadmill 
Running 
12.0 m/min 60 min/day 5 days/week 3 months 
Kang et al 
2013 
Treadmill 
Running 
10 m/min 60 min/day 5 days/week 5 weeks 
Gimenez-
Llort et al 
2010 
Treadmill 
Running 
4.2 m/min 30 min/day 5 days/week 5 weeks 
Ke et al 
2011 
Treadmill 
Running 
10 m/min 60 min/day 5 days/week 5 weeks 
Liu et al 
2011 
Treadmill 
Running 
11 m/min 30 min/day 5 days/week 5 months 
Liu et al 
2013 
Treadmill 
Running 
11 m/min 30 min/day 5 days/week 5 months 
Garcia-Mesa 
et al 2011 
Wheel 
Running 
Not 
reported 
12 hr/day 7 days/week 6 months 
Garcia-Mesa 
et al 2012 
Wheel 
Running 
4.0 m/min 12 hr/day 7 days/week 6 months 
Garcia_Mesa 
et al 2016 
Wheel 
Running 
3.3 m/min 12 hr/day 7 days/week 3 months 
Xiong et al 
2015 
Treadmill 
Running 
15 m/min 300 m/day 6 days/week 5 months 
Zhao et al 
2015 
Treadmill 
Running 
11 m/min 30 min/day 5 days/week 5 months 
Yuede et al 
2009 
Wheel 
Running 
10.9 m/min 60 min/day 5 days/week 4 months 
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Yuede et al 
2009 
Treadmill 
Running 
10.9 m/min 60 min/day 5 days/week 4 months 
Moore et al 
2016 
Treadmill 
Running 
15 m/min 
and 
32 m/min, 
10% grade 
60 min/day 5 days/week 3 months 
 
Overview of Physical Activity in AD Transgenic Mouse Models. Physical 
activity as a method of decreasing cardiovascular disease risk has been studied using 
animal models for more than 50 years. This body of work is highly sophisticated in its 
construction of physical activity paradigms which assess the intensity, volume, and mode 
of physical activity and exercise training and the relationship of those variables to 
reducing cardiovascular disease risk. In contrast, physical activity has been investigated 
as an intervention against AD pathology in transgenic mouse models for only slightly 
over a decade beginning with the study of Adlard et. al. published in 2005. Except for 
Moore et al. (2016) these studies have not quantified physical activity in a manner that 
would allow the assessment of the effect of physical activity level on reducing risk of 
developing AD pathology.   
Physical activity and exercise training studies using AD transgenic mouse models 
have utilized running wheels or motor driven treadmills in the administration of these 
treatments.  As with all treatment programs, there are advantages and disadvantages to 
each mode of physical activity.  Running wheels are advantageous in that they allow for 
voluntary activity for the animals, however, their disadvantage is that they do not allow 
for precise regulation of the intensity nor the volume of the activity in which the animals 
engage. With running wheels, it is not difficult to quantify the distance a mouse covers 
during a period of time (i.e., a 12 or 24 hour period), but it is not possible to know 
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anything about the manner in which the mouse covered that distance.  For example, some 
mice will run in the wheel at a constant, slow speed, whereas, others will run in bursts of 
high speed followed by periods of no activity.   
Another problem with wheel running is that there is a wide variation in running 
distance among animals within a study, making data interpretation difficult because 
health benefits of physical activity and exercise training are related to the amount of 
physical activity performed (Bherer et al., 2013; Noble et al., 1999).  Treadmill running, 
on the other hand, allows for precise regulation of exercise training, but has been 
criticized as being a stressful intervention (Yanagita, et al., 2007). This could be 
detrimental in the study of AD as it has been demonstrated that stress accelerates plaque 
development and cognitive decline in AD transgenic mice (Dong et al., 2004; Yuede et 
al., 2009). The work of Yuede et al. (2009), comparing voluntary wheel running and 
treadmill running to sedentary controls does not fully support this concern however. 
Plaque counts were found to be lower in Tg2576 mice subjected to wheel running than 
those subjected to treadmill running. However, mice running on treadmills had lower 
plaque counts than sedentary mice, indicating treadmill running was an improvement 
over a sedentary lifestyle. Wheel running mice did have lower plaque count than 
treadmill running mice. In addition, however, hippocampal volume was similar between 
wheel running and treadmill running mice and both were greater than sedentary mice.   
It is important in studies of physical activity and exercise training that some 
measure of improved physical fitness is assessed to demonstrate a training effect. This 
generally takes the form of an increase in maximum oxygen consumption of the animal 
or an increase in one of the mitochondrial oxidative enzymes in a working skeletal 
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muscle, the classic being citrate synthase (CS). To date only Moore et al. (2016) have 
done this in a study using an AD transgenic mouse model. When comparing wheel 
running to treadmill running, it has been demonstrated in rats that treadmill running 
results in increased soleus muscle CS activity (Bedford et al., 1979; Hilty et al., 1989), 
whereas, voluntary wheel running does not demonstrate this even when animals are 
divided into high and low running groups (Rhodes et al., 2005; Yancey and Overton, 
1993; Noble and Farrell, 1994).  Therefore, future study of physical activity and exercise 
training effects on delaying the onset and slowing the progression of the disease process 
in AD transgenic mouse models should utilize treadmill running to precisely regulate 
exercise intensities and volume.    
Effects of Physical Activity on Soluble Aβ and Plaque. The Aβ peptide is 
normally present in the interstitial fluid of the brain in soluble form throughout life 
(Cirrito et al., 2003). In AD pathology, Aβ aggregates into toxic soluble oligomers and 
eventually insoluble plaque in a concentration dependent manner (Bero et al., 2011). 
Therefore, strategies, including physical activity, aimed at reducing soluble Aβ in the 
brain prior to disease onset have been investigated as a method of delaying the onset and 
slowing the progression of AD pathology.   
 AD transgenic mouse studies investigating the effects of physical activity on 
amyloid pathology have been equivocal. Physical activity has been shown to either 
decrease (Adlard et al., 2005; Lararov et al., 2005; Um et al., 2008; Yuede et al., 2009; 
Liu et al., 2013; Tapia-Rojas et al., 2016) or not change (Cracchiolo et al., 2007) brain 
amyloid plaque levels.  Likewise, brain soluble Aβ levels have been found to decrease 
(Adlard et al., 2005; Um et al., 2008) or not change (Yuede et al., 2009) with physical 
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activity.  A likely explanation for the equivocation is the differences in the physical 
activity paradigms among the studies. As stated above, some used wheel running others 
treadmill running. It is entirely possible that the variation in intensity of physical activity 
in these studies accounted for the different results. 
 To address this likelihood, Moore et al. (2016) conducted a study to more 
thoroughly investigate the effect of physical activity dose on soluble Aβ levels in the 
hippocampus and cortex of Tg2576 mice. Three groups were utilized, a sedentary group, 
a moderate intensity treadmill running group (15 m/min on a level treadmill), and a high 
intensity group (32 m/min, 10% treadmill grade).  All animals in the treatment groups ran 
for 60 minutes per day, five days per week, for 12 weeks. The sedentary animals were 
placed on a stationary treadmill for an equal amount of time each day. The results 
demonstrated a clear dose-response of Aβ40 and Aβ42 to exercise training intensity.  
Additionally, the study demonstrated that the reduction of Aβ40 and Aβ42 was due to 
increased clearance as measured by a dose dependent upregulation of the Aβ degrading 
enzymes neprilysin, IDE, and MMP9, the blood brain barrier transport protein, LRP1, 
and the molecular chaperone, HSP70.  The moderate intensity treadmill running protocol 
in this study was more intense than the physical activity protocols in most of the previous 
studies summarized in Table 1. This indicates a likely minimum physical activity 
intensity threshold below which the effect of the physical activity is not realized and 
suggests that investigators in the future much more precisely assess physical activity 
levels in the study of physical activity effects on AD pathology. 
 It is also likely that the differences among studies investigating physical activity 
on amyloid plaque in AD transgenic mice can be attributed to differences in physical 
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activity intensity as described above for soluble Aβ.  At this point no study has been 
made of the effect of physical activity intensity on amyloid plaque.  It will be the purpose 
of the study undertaken here to do so. 
 Physical Activity on Tau. Studies of the effect of physical activity on Tau and 
NFPs have been limited compared with those investigating Aβ.  Belarbi et al. (2011) 
looked at the effects of 9 months of voluntary physical activity in THY-Tau22 mice and 
there was prevention of memory alterations, cholinergic defects, inflammatory and 
metabolism related modifications. Treadmill running has been shown to ameliorate the 
accumulation of phosphorylated tau in AD mouse models (Stranahan et al., 2012). In a 
long-term exercise training study, general locomotor and exploratory activity were 
exhibited in P301S tau transgenic mice along with reductions in full-length and 
hyperphosphorylated tau (Ohia-Nwoko et al., 2014). 
 Physical Activity and other factors. Symptoms such as weight loss, fatigue, 
decreased food intake, and weakness have been demonstrated in AD patients who are 
inactive. Physical activity in the form of a structured exercise paradigm may be beneficial 
to AD patients by improving learning, plasticity, angiogenic factors, cerebrovascular 
function and lower production of Aβ42 (Walsh et al., 2002). 
 High levels of Aβ42 deposition mediates apoptosis of neuronal cells or apoptosis 
itself. But exercise training improves neuronal function by modulating neurogenesis, 
synaptic plasticity, learning, and memory (Kuperstein et al., 2010). However, the 
mechanisms by which apoptosis is modulated by exercise training in AD remains 
uninvestigated. De Strooper (2011) evaluated exercise training to determine whether it 
could prevent or improve cell death in the brains of transgenic (Tg) mice, as found in AD 
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patients. The study demonstrated that caspases, Bax protein levels, and cytochrome c 
were significantly reduced in Tg mice brains that were exercised trained compared to 
sedentary control.   
 Pro-apoptotic protein (cytochrome c and Bax) reduction post exercise training in 
APP Tg mice may be mechanistically related to lower Aβ42 levels which may be 
mediated through apoptotic pathway inhibition (Anderson et al., 1996). Importantly in 
this study, the Tg mice brains had elevated levels of Bcl-2, an apoptotic protein, 
compared to sedentary control. This observation is critical because a previous study 
demonstrated that exercise training can result in neuronal resistance against oxidative and 
apoptotic damages mediated through reduction in Aβ-induced apoptosis (Molteni et al., 
2002). Therefore, these results suggest that apoptosis of neurons responsible for AD 
pathogenesis can be modulated by exercise training which increases the clearance of Aβ.  
 Neurotrophic factors such as NGF, BDNF and CREB, which are known to link 
adult hippocampal neurogenesis and hippocampal function were decreased in AD and are 
clinically associated with Aβ42 depositions in the brain of AD animals and patients. 
Therefore, establishing the rationale for using treadmill exercise training as non-
pharmacological approach for elevating neurotrophic factors has received the greatest 
attention from AD investigators (Lesne et al., 2006).  
 Chen and Russo-Neustadt (2009) demonstrated that hippocampal NGF, BDNF 
and CREB levels were down-regulated in Tg mice compared with non-Tg mice, but they 
were up-regulated after treadmill exercise training, indicating that treadmill exercise 
training increased levels of hippocampal NGF, BDNF and its downstream effectors 
CREB, which are important for cognitive function in Tg-NSE/PS2m mice. The 
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underlying molecular mechanisms could indicate that treadmill exercise training has the 
potential to enhance cognitive function in Tg-NSE/PS2m mice, possibly through an 
increased level of NGF, BDNF and CREB, which are important for neurogenesis in the 
hippocampus. This result indicates that treadmill exercise training has a better ability to 
induce antioxidant enzymes to cope with the oxidative stress formed in the brain of Tg 
mice with AD.  
 Heat shock proteins (HSPs) are ubiquitously expressed intracellular proteins that 
protect proteins and DNA from stress-induced damage. HSP-70 has been reported to 
inhibit the self-assembly of poly-glutamine proteins into amyloid-like fibrils. However, 
till recently, it was not known whether HSP-70 increases within the brains of AD-
transgenic mice during exercise training (Hardy, 2005). Jones et al. (2010) showed that 
hippocampal HSP-70 level was down-regulated in Tg mice compared with non-Tg mice, 
and that the level of this protein in Tg mice was up-regulated after treadmill exercise 
training (Jones et al., 2010). Moore et al. (2016) demonstrated that HSP-70 was elevated 
by treadmill exercise training in a dose-dependent manner. These findings indicate that 
treadmill exercise training contributes to a neuroprotective effect on the brain of Tg mice 
with AD, suggesting that increased level of HSP-70 protein following treadmill exercise 
training may benefit the brain, making it more resistant to stress induced cell damage 
(Mosser et al., 1997; Broer et al., 2011).   
 Exercise training is suggested to reduce Aβ accumulation in cortical areas of AD 
transgenic mouse by increasing proteolytic degradation by proteasome. The exact 
molecular mechanisms underlying these favorable effects of exercise training in brain are 
not well known, but the MAPK, PI3K, and PI/Akt signaling pathways and the 
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transcription factor CREB have been involved at the molecular level (De Strooper, 2010). 
Exercise training also can change the function of glutamatergic systems, increasing 
NMDA receptor in the hippocampus, which are crucial in learning and memory 
processes. The health and psychological benefits elicited by regular physical activity in 
older adults contribute to healthy aging. Therefore, physical exercise training is a 
potential intervention to preserve or ameliorate cognitive function and behavior in AD 
(Khachaturian et al., 2011). 
 Taken together, any or all of the above-mentioned proteins are potential triggers 
for the neuronal cell death and survival. Therefore, studies investigating death and 
survival of neuronal cells exposed to AD would be a step in the search for therapy 
leading to recovery from AD and explanation of molecular mechanism responsible for 
the effect of therapeutic interventions such as exercise training to repress neuronal cell 
death (Yuan et al., 2003; Kang et al., 2013). 
In summary, several studies in transgenic mouse models of AD suggest exercise 
training reduces soluble and insoluble Aβ levels in the brain. Epidemiological studies 
suggest that physical activity exerts beneficial effects on humans. But as reviewed 
extensively here, the lack of a specific exercise paradigm raises the question of 
quantifying exercise training in a controlled experimental setting to address dose-
dependent beneficial effects. This study is the second part of an investigation into the 
dose response of exercise training on AD pathology.  In the first part, Moore et al. (2016) 
demonstrated that three months of exercise training in young Tg25756 mice reduced 
soluble Aβ40 and Aβ42 and upregulated multiple Aβ clearance proteins in an exercise 
training dose dependent manner.  This study extended the treadmill running employed by 
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Moore et al. (2016) to 12 months in the same mouse model and investigated its effect on 
amyloid plaque levels in the cortex and hippocampus and on cognitive function. 
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MATERIALS AND METHODS 
Animals  
This study was approved on 17 September 2010 by the Institutional Animal Care 
and Use Committee (IACUC), protocol number 10024. Tg2576 mice, from our in-house 
colony, expressing human APP695 with double mutations K670N and M671N driven by 
the hamster prion protein [147] were used for this study. Hemizygous male Tg2576 mice 
maintained on C57B6/SJL background were crossed with wild type C57B6/SJL females. 
Only male Tg2576 offspring were used in this study. Animals were housed individually 
in Optimize ventilated cages and provided food and water ad libitum. Tail snips were 
acquired at the time of weaning, 3 weeks of age, to confirm transgene expression. 
Genotyping was performed using a QIAGEN QIAamp Mini Kit (cat. no. 51304, 
Valencia, CA) to purify DNA, followed by RT-PCR analysis.  
 
Experimental Design 
Animals in high intensity (HI) and low intensity (LOW) groups were placed on a 
motor driven treadmill (Columbus Instruments, Columbus, OH) with an electric grid for 
motivation for 1 hour each day, 5 days per week, for 12 months. LOW animals ran at a 
speed of 15 m/min, 0% grade. HI animals ran at a speed of 32 m/min, 10% grade, as we 
have previously observed that most animals are able to run at this speed for one hour 
daily (Moore et al., 2016). Sedentary (SED) animals were removed each day from their 
home cage and placed on an immobile treadmill to keep handling and environmental 
stimuli consistent among groups. 
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Table 2: Summary of experimental design. 
 HI LOW SED 
Age at beginning of 
exercise training 
3 months 3 months 3 months 
Run time 12 months 12 months 
 
N/A 
Speed 32 m/min,10% 
grade 
15 m/min, 0% 
grade 
N/A 
 
Age at time of 
behavioral analysis 
 
 
 
14 months 
 
 
 
 
14 months 
 
 
 
 
14 months 
Age at end of 
Exercise training 
15 months 15 months 15 months 
 
Body Weights and Food Intake 
 Body weights of animals were monitored once at the end of every month during 
the 12-month exercise training strategy. Baseline weights were recorded prior to the 
training strategy. At the end-point, food consumption was monitored over 24 hrs prior to 
sacrifice. All animals were individually housed so 30 grams of food was weighed and 
provided to their home cages. 24 hrs later, food was weighed again and subtracted from 
the previous weight.  
Tissue Preparation 
Animals were sacrificed at the end of month 12 of treatment by isoflurane. Brains 
were promptly removed and immersed in 4% paraformaldehyde for 24 hrs then 
transferred to a 30% sucrose solution to store for later histological analysis. The soleus 
muscle was collected from each hind limbs and snap frozen on dry ice, and then stored at 
-80 °C for citrate synthase analysis. 
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Citrate Synthase Analysis 
 Following sonication in CellLytic MT buffer, soleus muscle citrate synthase (CS) 
activity was assessed (Sigma Aldrich Citrate Synthase Enzyme Activity Kit, Appendix 
A-1). Absorbance was measured at 412 nm on a BioTek Epoch plate reader and values 
for left and right soleus muscles of each animal were averaged. Total protein was 
quantified (Thermo Scientific™ Pierce™ BCA™ Protein Assay). 
 
Tissue Sectioning and Amyloid Plaque Staining 
Brain hemispheres were mounted for sectioning using Tissue-Tek® Optimal 
Cutting Temperature (O.C.T.) compound (Electron Microscopy Sciences, Hatfield, PA). 
Using a cryostat (Microm HM550, ThermoFischer Scientific, Walldorf, Germany), 
coronal sections 40 µm thick were taken at the level of the hippocampus (5.5 mm deep) 
and every 8th section was saved for staining.  
DAB Staining. Sections were fixed and stained using mHJ3.4B, a biotinylated 
reporter antibody specific to N-terminus of Aβ. After incubation with streptavidin-HRP, 
Aβ plaques were detected by DAB and viewed using light microscopy. Plaque area in the 
cortex and hippocampus was determined using NIH Image J software. Images were 
captured for plaque staining at 40X magnification (Appendix A-2). 
Thioflavin S Staining.  Plaque staining was also analyzed with Thioflavin S 
staining. Slides were incubated in filtered 1% aqueous Thioflavin-S (Sigma) for 5 min, 
dehydrated twice in 70% ethanol for 5 min, and washed twice in PBS for 2 min. Mosaic 
images were captured for amyloid plaque staining at 10X magnification (Appendix A-2).  
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Behavioral Analysis 
Mice were subjected to behavioral analyses during the last two weeks of treatment 
in the form of open field, Morris water maze (MWM) and novel object recognition 
(NOR) testing to evaluate spatial and recognition memory. Behavioral analysis was 
tracked in real time by an overhead camera and videos were analyzed using the ANY-
Maze software (Stoelting Co). 
 Open Field. Mice were placed in the center of a white box (l38.5xw30xh30 cm) 
and allowed to move freely for 10 min. The distance traveled and average speed were 
measured using the Any-Maze software (Appendix A-3). 
Morris Water Maze.  Morris Water Maze testing was conducted in a 150 cm 
diameter pool divided into four equal quadrants with the “goal quadrant” containing a 
submerged platform that the mice had to find. Mice had a 7 day acquisition period with 
four 60 second trials per day. Two days of cued trials first took place in which a tennis 
ball denoted platform location. Four trials per cued day occurred where the submerged 
platform was cycled through each quadrant. Mice were started opposite to the goal 
quadrant in each of these trials. Five days of place trials then followed the cued trials. For 
each of these successive trials, black shaped cues were placed on the walls surrounding 
the pool and mice were started in a different quadrant using a random start pattern. In 
both the cued and place trials latency (time to find platform) was recorded with a 
maximum of 60 seconds allowed. If the animal did not find the platform within 60 
seconds it was led to the platform. All animals, whether or not they found the platform, 
were allowed to remain on the platform for 30 seconds. A single probe trial was 
evaluated after a one hour delay following the last place trial. The platform was removed 
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for the probe trial and percentage of time spent in the goal quadrant was recorded. All 
MWM trials were evaluated using ANY-maze video tracking system (Stoelting Co., 
Wood Dale, IL) (Appendix A-4). 
Novel Object Recognition. Mice were first acclimated to the test area for 20 
minutes, one day before testing. On test day, each mouse had a sample trial and a test 
trial. During the sample trial, the mouse was exposed to two identical objects for 10 
minutes before returning to the home cage. After a 50 minute delay, the mouse was put 
back into the test area for the test trial with one of the objects from the sample trial and a 
novel object and exposed to the objects for 10 minutes. Test areas were cleaned with 70% 
ethanol after each trial. Sample and trial sessions were recorded using ANY-maze 
software. The time the animal spent with each object was assessed using a manual 
stopwatch.  Active investigation was described as facing the object within close 
proximity (2 cm) and/or touching the object with forepaws. The amount of time spent 
investigating the objects was recorded and the time spent investigating the novel object as 
compared to the familiar object was analyzed as a measure of recognition memory (Leger 
et al., 2013) (Appendix A-5).  
Statistical Analysis 
Experimenters were blinded during data analyses. Repeated measures ANOVA 
was used to determine whether there was significant effects of treatment between objects 
in object recognition test with exercise treatment (SED, LOW, HI) as the between-
subjects factor and the two objects (top, bottom; familiar, novel) as the within-subjects 
factor. Repeated measures ANOVA was also used to determine whether there was 
significant effects of treatment status between places trial days in MWM with exercise 
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treatment as the between-subjects factor and the five days of place trials as the within-
subjects factor. One-way ANOVAs were performed to evaluate treatment effects on total 
investigation times in sample and test trials for object recognition and probe trails using 
MWM. One-way ANOVA was also used to analyze treatment effects on anxiety levels 
by total distance in the arena and time spent in the center zone in the open-field test. 
For body weights and food consumption, One-way ANOVA was used to evaluate 
treatment effects between groups. Citrate synthase levels and amyloid-beta plaque levels 
were analyzed using One-way ANOVA between groups as well. 
All analyses were performed using GraphPad Prism version 6 with statistical 
significance set at p < 0.05. If ANOVA suggested significant effects of group, Tukey’s 
post-hoc comparison was used to evaluate between group differences. All data are 
presented as mean +/- SEM.  
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RESULTS 
Body Weight and Food Intake 
Sedentary (SED), High Intensity Exercise (HI), and Low Intensity Exercise 
(LOW) groups all progressively increased in body weight throughout the course of the 
study (Figure 4).  Body weight did not differ among groups during the course of the study 
(Appendix B-1). 
 
                    
Figure 4: Body weight increased similarily in mice in all three groups during the 12 
month duration of the study. Mice were three months old when training began. (SED, 
n=4; LOW, n=9; HI, n=5).  
 
At the 14 month time point, food intake was assessed to check for a potential 
exercise training effect on appetite. There were no differences in food intake among 
groups over 24 hours (Figure 5, Appendix B-2). 
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Figure 5: Food intake of mice, monitored over one 24-hour period, at the end of the 
treatment program. Error bars represent SEM (SED, n=4; LOW, n=9; HI, n=5). Groups 
are not statistically different from one another.  
 
Citrate Synthase  
 Citrate synthase (CS) activity measurement is a standard test for assessing an 
exercise training effect in mice. CS activity was significantly different among all three 
groups (Figure 6). The HI group had a 110% increase in CS activity compared to the 
LOW group and a 425% increase compared to the SED group. The LOW group had a 
149% increase in CS activity compared to the SED. Thus, indicating a clear dose 
response of the treadmill exercise paradigm in the groups (Appendix B-3). 
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Figure 6: Citrate Synthase Activity. Values are expressed as activity of a gram of soleus 
muscle/min.  Error bars represent SEM (SED, n=4; LOW, n=9; HI, n=5). One-way 
ANOVA and Tukey’s post hoc analysis: **significant at p < 0.0017, ***significant at p < 
0.0001. 
 
 
Amyloid Plaque 
 As Tg2576 mice are a model of AD, amyloid plaque levels were assessed after 12 
months of exercise training via immunohistochemistry methods. Amyloid plaque load 
was impacted by exercise training in both the cortex and hippocampus in a dose 
dependent manner (Figure 7).  The HI group had significantly lower percent area in the 
cortex than the LOW (45.2%) and SED (58.5%) groups and the LOW group was 
significantly lower than SED (24.4%). In the hippocampus the HI group plaque area was 
significantly lower than the LOW (83.3%) and SED (88.6%) groups and the LOW group 
was significantly lower than SED (31.4%). Representative images of plaque in the cortex 
are shown in Figure 8 (Appendix B-4). 
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Figure 7: A. Percent area of amyloid plaque in cortex. Values are expressed as 
percentage of area in the cortex covered by amyloid plaques. Error bars represent SEM 
(SED, n=6; LOW, n=6; HI, n=5). One-way ANOVA and Tukey’s post hoc analysis: * 
significant at p <0.016, ** significant at p < 0.0054, *** significant at p < 0.0001. B. 
Percent area of amyloid plaque in hippocampus. Values are expressed as percentage of 
are in the hippocampus covered by amyloid beta plaques. Error bars represent SEM 
(SED, n=6; LOW, n=6; HI, n=5). One-way ANOVA and Tukey’s post hoc analysis: ** 
significant at p < 0.0007 between the SED and LOW groups and ** significant at p < 
0.0006 between the LOW and HI groups, *** significant at p < 0.0001 
 
 
 
Figure 8: A. Representative images of ThioS staining of amyloid plaques at 10X 
magnification. Orange arrows point towards the plaques in the cortex. Amyloid plaques 
are lower in the HI group compared to the LOW and SED groups. Plaques are also lower 
in the LOW group compared to the SED group. B. Representative images of DAB 
staining of amyloid plaques in the cortex at 40X magnification. Amyloid plaques are 
significantly lower in the HI group compared to the LOW and SED groups. LOW group 
has lower plaques compared to SED group. 
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Behavior 
Open Field.  A potential confounding factor for the beneficial effects of high 
intensity treadmill exercise is whether the exercise routine modulates anxiety-like 
behavior. In the open field test, there were no differences in total distance covered and 
distance in middle grid between the HI, LOW, or SED groups (Figure 9, Appendix B-5).  
                                     
 
 
 
Figure 9: Open Field Test – Locomotor Activity. Values are expressed as total distance 
covered in the open field arena in area units. Error bars represent SEM (SED, n=4; LOW, 
n=9; HI, n=5). One-way ANOVA. No significant differences between groups.                                      
 
 
Morris Water Maze.  Spatial memory was investigated using a Morris water 
maze test. In the acquisition phase (Figure 10A), The HI group latency to the platform 
was significantly lower on days 3, 4, and 5 compared to day 1.  The LOW and SED 
groups latency to the platform  was significantly lower on day 4 compared to day 1 with 
LOW being lower on day 5, but SED day 5 latency was not significantly different from 
day 1. In the probe trial (Figure 10B and C), the HI group had a significantly faster time 
to the platform location and spent a longer time in the target quadrant compared to the 
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LOW and SED groups.  The LOW group had a significantly faster latency to the platform 
location than the SED group, however, the time spent in the target quadrant was not 
different between the LOW and SED groups.  Swimming speed was not different among 
groups (Figure 10D, Appendices B-6 and B-7).   
 
 
Figure 10: A. Morris water maze-acqusition phase. The HI group improved performance 
compared to the LOW and SED groups. Error bars represent SEM (SED, n=5; LOW, 
n=10; HI, n=6). B. Morris water maze-probe trial. The HI group had lower latency to 
platform compared to the LOW and SED groups. Error bars represent SEM (SED, n=5; 
LOW, n=10; HI, n=6). One-way ANOVA and Tukey’s post hoc analysis: ** significant 
at p < 0.0019, *** significant at p < 0.0001. C. Morris water maze-probe trial. The HI 
group spent more time in target quadrant compared to the LOW and SED groups. Error 
bars represent SEM (SED, n=5; LOW, n=10; HI, n=6). One-way ANOVA and Tukey’s 
post hoc analysis: *** significant at p < 0.0001). D. Morris water maze-probe trial. 
Values expressed as swim speed in meters per second. Error bars represent SEM (Sed, 
n=5; Mod, n=10; HI, n=6). One-way ANOVA. No significant differences between 
sedentary, moderate, and high intensity groups. 
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Novel Object Recognition.  All groups investigated the similar objects equally at 
approximately 50% in the sample trial (Figure 11A). In the test trial, the high intensity 
mice investigated the novel object significantly more compared to the LOW and SED 
groups which investigated the novel object and familiar object equally.  Total object 
investigation time did not differ among groups (Figure 11C, Appendices B-8 and B-9). 
      
 
Figure 11: A. Object recognition test-sample trial. All groups spent the same amount of 
time investigating the two similar objects within groups. Error bars represent SEM (SED, 
n=9; LOW, n=10; HI, n=7). No significant differences existed among groups. B. HI 
group spent more time investigating the novel object compared to the familiar object. 
One-way ANOVA ad Tukey’s post-hoc analysis: *** significance at p < 0.0002. Error 
bars represent SEM (SED, n=9; LOW, n=10; HI, n=7). No significance existed between 
novel and familiar object recognition in LOW and SED groups. Object recognition test-
testing phase. C. All groups had similar total investigation times. No significant 
differences existed between groups. Error bars represent SEM (SED, n=9; LOW, n=10; 
HI, n=7).  
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DISCUSSION 
Soluble Aβ is present in the interstitial fluid in the brain throughout life and 
aggregates into amyloid plaques later in life in a concentration dependent manner 
(Lomakin et al., 1997). Bero et al. (2011) published a definitive study on this topic 
demonstrating, using microdialysis, a tight relationship between ISF Aβ early in life and 
subsequent plaque deposition in aged mice in four different areas of the brains of Tg2576 
mice. The findings of Bero et al. (2011) formed the conceptual basis for the two part 
study performed in our lab of which the work reported here is the second part. In the first 
part, Moore et al. (2016) found that soluble Aβ levels early in life were lower in the 
cortex and hippocampus of Tg2576 mice that were exercise trained by treadmill running. 
They further demonstrated that this effect was dose-dependent, in other words, the greater 
the exercise training intensity the lower the soluble Aβ levels in both brain areas 
assessed. This study utilized the exercise training paradigm of Moore et al. (2016), but 
rather than stopping the training period at six months of age it was continued until 15 
months of age to determine whether or not the amyloid plaque levels in the 12 month 
exercise trained animals were reduced in a similar dose-dependent manner as the soluble 
Aβ levels in the younger trained mice. This study also determined the effects of the 
exercise training program on behavioral tests of anxiety, spatial memory, and recognition 
memory.  
Body Weight and Food Intake 
High intensity treadmill exercise training, as employed in this study, could 
potentially affect food intake and body weight of the mice. Studies throughout literature 
overlook these factors during or post physical activity training, possibly because of lower 
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running speeds or length of exercise regimen. Therefore, in the present study we 
addressed this issue to identify potential negative peripheral effects of 12 months of 
continuous treadmill exercise training. 
It has been speculated that prolonged physical exercise could affect body weight 
(Chaput et al., 2011). Therefore, we monitored body weight once each month over the 
12-month exercise regimen.  All groups progressively increased in weight, without any 
significant differences among groups throughout the duration of the study. Various 
studies report that wild-type and transgenic mice increase in weight as they age, 
indicating that weight-increase over the lifetime of male mice is a natural effect (Inui, 
2000; Ellacott et al., 2010; Gargiulo et al., 2014; List et al., 2014). The effect of exercise 
training on body weight in mice is equivocal with some indicating that body weight does 
not change in exercise trained mice and is lower than sedentary control mice (McMullan 
et al., 2016; Toti et al., 2011), whereas, others (Evangelista et al., 2015; Kemi et al., 
2002) found no difference in body weight between sedentary and exercise trained mice.  
The data from this study are similar to those of Evangelista et al. (2016) and Kemi et al. 
(2002).  The effect of exercise training on body weight in mice varies with different 
studies for reasons that are not entirely clear.  It may have something to do with the 
intensity, duration and mode of the exercise training programs. A concern for us was that 
the high intensity training regimen for a continuous 12-month duration may be stressful 
to the animals, which may lead to weight loss. But the high intensity exercise trained 
mice gradually increased in weight just as the low and sedentary groups, further 
indicating that the mice adapted to the exercise intensity training regimen, which did not 
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affect their ability to naturally gain weight as they aged. However, mechanisms related to 
metabolism and weight gain/loss in exercise trained mice remains to be elucidated.  
At the 14 month time point, food intake in all groups was assessed to determine 
whether or not exercise training affected appetite. There were no differences in food 
intake assessed 24 hours after the last day of training in any of the groups. These data 
indicate that the exercise regimen employed in this study did not affect food intake 
despite increased activity during exercise training between the high intensity, low 
intensity, and sedentary groups. Future experiments monitoring food consumption more 
regularly are needed to determine mechanisms relating to exercise treatment. 
Assessment of Exercise Training  
With the exception of Moore et al. (2016) from our laboratory no previous studies 
investigating the role of physical activity in delaying the onset or slowing the progression 
of Alzheimer’s pathology in AD transgenic mouse models attempted to assess the degree 
of an exercise training effect. Like our pervious study we used citrate synthase activity in 
this study as a measure of an exercise training effect. We found a 149% increase in CS 
activity in the low intensity group compared to sedentary, a 425% difference between the 
high intensity group compared to sedentary, and a 110% increase in activity of the high 
intensity group compared to the low intensity group. These results indicate a clear dose-
dependent exercise training effect in the animals in this study.  
When using citrate synthase activity as a marker of an exercise training effect it is 
important that muscle samples are not harvested immediately following an exercise bout 
as it has been demonstrated that citrate synthase activity is elevated following an acute 
exercise bout (Leek et al., 2001). It is therefore necessary to allow the mice sufficient 
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recovery between the last exercise bout and removal of the soleus muscle so the data are 
not influenced by the final exercise bout. It is also important, however, to not wait too 
long following the final exercise bout and muscle harvest as this could result in a 
detraining effect. In this study we waited 72 hours following the final exercise bout to 
harvest the soleus muscle as it appears from previous reports that this is a sufficient 
period to allow citrate synthase activity to return to steady state following acute exercise 
(Siu et al., 2003).  
The increases in CS activity in this study in both exercise trained groups 
compared to the sedentary group are greater than those of our previous study (Moore et 
al., 2016) where we found a 39% increase in CS activity in the low intensity group 
compared to sedentary and a 146% increase in CS activity in the high intensity group 
compared to the sedentary group. A possible explanation for this is that the mice in the 
previous study performed the exercise training program for three months whereas, the 
mice in the current study exercise trained for 12 months. The absolute numbers for the 
high and low intensity groups are not much different between the two studies, however, 
with high intensity group CS means being 128 and 139 µmol min-1 g wet weight-1 for the 
previous and current studies, respectively and the low intensity group CS means being 75 
and 66 µmol min-1 g wet weight-1, respectively for the previous and current studies. The 
sedentary groups differed by a fairly large margin between the studies (52 vs. 26 µmol 
min-1 g wet weight-1, respectively for the previous and current studies) which is the 
reason for the large percent difference between the studies in the low and high intensity 
group comparisons to the sedentary group. The reason for the large difference between 
sedentary group CS activity in these two studies is not readily apparent, although one 
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possibility could be the age difference as citrate synthase activity has been reported to be 
lower in gastrocnemius muscle of sedentary aged mice compared to sedentary young 
mice (Ryan et al., 2010).  
To date, the neuroscience community has not quantified the impact of physical 
activity paradigms in the context of exercise training effects in studies investigating its 
impact in reducing risk of pathology associated with neurodegenerative diseases. It is 
highly likely that the intensity and/or volume of the physical activity conducted by an 
individual is directly related to risk reduction of chronic neurological diseases such as 
Alzheimer’s as this is the case with other chronic diseases, primarily cardiovascular 
disease (Garber et al., 2011). In fact, this was demonstrated by our previous study (Moore 
et al., 2016). For this reason it is important that future studies investigating the effect of 
physical activity on reducing risk of neurological pathology assess the degree of a 
training effect, or lack thereof, produced by the physical activity paradigm utilized in the 
study.  
Amyloid Plaque  
Aβ deposition is a hallmark of AD pathogenesis. Aβ is normally present in the 
ISF of the brain in soluble form throughout life (Cirrito et al., 2003). In AD pathology, 
Aβ aggregates into toxic oligomers and eventually insoluble plaque in a concentration 
dependent manner (Bero et al., 2011). Therefore, strategies, including physical activity, 
aimed at reducing soluble Aβ in the brain prior to disease onset have been investigated as 
a method of delaying the onset and slowing the progression of AD pathology.  
In the previous study from our laboratory, Moore et al. (2016) demonstrated that 
three months of exercise training in the form of treadmill running at two different 
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intensities (15 m/min on a level grade and 32 m/min on a 10% grade for one hour per 
day, five days per week) reduced ISF concentrations of soluble Aβ40 and Aβ42 in a dose 
dependent manner in the cortex and hippocampus of young Tg2576 mice. It was further 
demonstrated that a number of soluble Aβ clearance proteins were upregulated, the 
degree of which was also exercise training dose-dependent, indicating that the lower 
soluble Aβ levels were the result of increased Aβ clearance through multiple 
mechanisms. These mechanisms included; 1) increased activity of Aβ degrading enzymes 
NEP, IDE, and MMP-9, 2) upregulation of LRP1 increasing Aβ efflux from the brain 
across the blood-brain barrier, and 3) upregulation of HSP-70 increasing Aβ stabilization 
preventing aggregation. The work of Bero et al. (2011) suggests that if Tg2576 mice were 
subjected to the same exercise training protocol as used by Moore et al. (2016) for a 
prolonged period of time there should be a dose-dependent reduction in amyloid plaque 
load later in life. The results of this study support that hypothesis as the percentage of the 
area containing amyloid plaques in both the cortex and hippocampus of the mice used in 
this study was significantly decreased in an exercise intensity dose-dependent manner. 
Taken collectively, the results of this study and those of Moore et al. (2016) provide 
support for the concept that brain amyloid plaque levels late in life are closely related to 
soluble Aβ levels in early life and that strategies employed to keep ISF soluble Aβ levels 
low early in life do, in fact, lead to reduced plaque levels in later life.  
The data from this study provide clarification to previous studies into the effects 
of physical activity interventions on amyloid plaque load in AD transgenic mice which 
have been equivocal. Most studies have reported reduced amyloid plaque load as a result 
of physical activity (Adlard et al., 2005; Lazarov et al., 2005; Um et al., 2008,2011; 
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Yuede et al., 2009; Liu et al., 2013), however others have not found physical activity to 
reduce amyloid plaque load (Cracchiolo et al., 2007). None of these previous studies have 
considered the issue of the dose-dependence of exercise training on amyloid plaque 
development. It is therefore, likely that the disparate results are due to differing 
intensities of the physical activity paradigms employed in these studies. For this reason it 
is recommended that all future studies investigating physical activity effects on reducing 
AD pathology assess the exercise training impact using some objective measure such as 
citrate synthase activity.  
Another reason for differences among the studies mentioned above could be the 
method used to deliver the physical activity as some studies utilized running wheels 
(Adlard et al., 2005; Lazarov et al., 2005; Cracchiolo et al., 2007; Yuede et al., 2009) and 
some used motor driven treadmills (Um et al., 2008,2011; Yuede et al., 2009; Liu et al., 
2013; Moore et al., 2016). It has been demonstrated that emotional stress accelerates 
amyloid plaque development in Tg2576 mice (Dong et al., 2004, 2008) and argued that 
treadmill running is not a good method of physical activity in studies using mice as it is 
an emotionally stressful intervention (Yanagita et al., 2007). Wheel running, on the other 
hand, is an activity that the mouse can perform at a time and intensity of its choosing and 
thus has the advantage of not being emotionally stressful. On the other hand, exercise 
training intensity cannot be controlled with running wheels as distance run on running 
wheels is highly variable among animals and is of low intensity as it has been 
demonstrated in rats that voluntary wheel running does not result in increased citrate 
synthase activity compared to sedentary control animals even when the animals are 
divided into high and low running groups (Nobel et al., 1999). A previous study from our 
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laboratory compared wheel running and treadmill running interventions in Tg 2576 mice 
and found that plaque counts were lower in wheel running mice that treadmill trained 
mice who ran at the same average speed as the wheel running mice. The running speed 
was extremely low, however (average of 10.9 m/min on a level treadmill), which likely 
did not produce an exercise training effect which unfortunately was not measured in that 
study. In future studies, investigating exercise training as a strategy for delaying the onset 
and slowing the progression of AD pathology it will be necessary to use treadmill 
running to control exercise intensity and volume, both of which are important 
contributors in AD risk reduction.  
Behavioral Assessment 
 
A prolonged forced exercise training may induce anxiety in mice which may 
affect treadmill running (Svensson et al., 2016). The open field test, an indicator of 
anxiety-like behavior, did not reveal any differences between the groups. This indicates 
that 12 months of forced exercise training did not cause anxiety in the mice and therefore, 
was unlikely to have an impact on the cognitive performance in the Morris Water Maze 
(MWM) or Novel Object Recognition (NOR) tests. These data are consistent with reports 
from Yuede et al. (2009) where forced treadmill exercise did not exhibit significant 
anxiety-like behavior in the open field test.  
In the MWM test the HI exercise trained group learned the location of the 
platform faster than the LOW and SED groups as their latency to the platform in the 
place trials significantly improved from day 1 to day 3 and continued to improve 
throughout the five days.  Analysis of simple main effects showed the performance of the 
LOW group significantly improved from day 1 to day 4 and five while the SED group 
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showed an indication of improved performance from day 1 to day 4 (day 1 to day 5 
comparison was not significant).  In the probe trial the latency to the platform location 
was far less for the HI exercise trained group than the LOW and SED groups and the 
latency to platform for the LOW group was significantly less than the SED group. 
Significantly improved spatial memory function is also demonstrated in the HI group by 
the increased time spent in the target quadrant relative to the LOW and SED groups. 
Swimming speed was not different among groups demonstrating that it was not a factor 
contributing to differences among groups in latency to platform during the place trial nor 
latency to platform location during the probe trial. To further evaluate behavioral changes 
resulting from the exercise training paradigms we subjected the mice to a NOR test to 
assess recognition memory. As with the MWM test, the HI group performed significantly 
better than LOW and SED, with the HI mice spending more time investigating the novel 
object than the familiar object compared to the LOW and SED groups.  The LOW and 
SED groups did not differ in time spent investigating the novel and familiar objects.   
Direct comparisons between our MWM and NOR data and those of others 
studying transgenic AD mice subjected to exercise training treatments using treadmill 
running are limited.  Um et al. (2008) subjected NSE/APPsw mice who ran 13.2 m/min 
on a level treadmill for 60 minutes a day, five days a week for 16 weeks and a sedentary 
group to a MWM test. Their reported mean initial latency to the platform location times 
in the probe trial for the sedentary and exercise trained groups were approximately 55 and 
35 seconds, respectively (times estimated from Fig 3c in their manuscript). Interestingly, 
these are very similar to the times for our SED (53.5 s) and LOW (39.9 s) groups. As for 
NOR, the only direct comparison is to the study of Yuede et al. (2009) from our 
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laboratory. In that study a group of Tg2576 mice subjected to treadmill running at an 
average speed of 10.9 m/min on a level treadmill for 60 min/day, five days/week did not 
differ from sedentary mice in preference for the novel object. This was also the case in 
this study with the LOW to SED comparison. The data from this study are in agreement 
with the previous studies with respect to behavior demonstrated in MWM and NOR 
testing in AD transgenic mice subjected to low intensity treadmill running.  
Taken collectively, our MWM and NOR data point to a clear dose-response of 
Tg2576 mice to exercise training. In all cases, high intensity exercise training results in 
significant, and dramatic, improvement in performance on both spatial and recognition 
memory tasks compared to SED mice. Low intensity exercise training does improve 
spatial memory over the sedentary condition as demonstrated by the improved latency to 
the platform location in the probe trial of the MWM test indicating this treatment is 
beneficial over the sedentary condition, however this difference is subtle.   
The mechanisms through which the “stair-step” dose response effect of the 
exercise training paradigm reduces amyloid plaque levels and improves cognitive 
function remains unknown. Although mechanistic and signaling targets such as glucose 
uptake, DNA repair, upregulation of neurogenic factors such as BDNF, increased levels 
of clearance proteins, and upregulation of angiogenesis are a few of the processes that 
may be modulated because of chronic physical activity, the mechanisms by which they 
are modulated remains uninvestigated. One way to measure a dose response could be to 
investigate cerebral blood flow. Although not consistently reported, increased cerebral 
blood flow to the brain post exercise may lead to increased brain metabolism (Querido 
and Sheel, 2007). Increased cerebral blood flow may also reduce the hypoxic condition of 
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AD brains, as hypoxia facilitates AD pathogenesis by up-regulating BACE1 gene 
expression (Sun et al, 2006), and may also modulate blood-brain barrier permeability, 
regional brain glucose content, and local glucose utilization.  
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SUMMARY, CONCLUSIONS AND FUTURE DIRECTIONS 
 
  In summary, these experiments have demonstrated that intensity and 
duration of exercise training are important factors in dissecting the link between physical 
activity and Alzheimer’s disease, and thus relevant to designing exercise training 
paradigms. The exercise training interventions in this study helped to address the 
beneficial effects of long-term treadmill exercise interventions in improving cognitive 
function and decreasing amyloid-beta plaque levels in a dose-dependent manner in an AD 
transgenic mouse model. More importantly, the dose response was quantified and 
demonstrated by a metabolic assay which has been absent in previous studies in the field 
of AD and neuroscience. The low intensity treadmill running protocol in this study was 
more intense than the physical activity protocols in most of the previous studies 
(summarized in Table 1). This indicates a likely minimum physical activity intensity 
threshold below which the effect of the physical activity is not realized and suggests that 
investigators in the future need to precisely assess physical activity levels in the study of 
physical activity effects on AD pathology. Therefore, future study of physical activity 
and exercise training effects on delaying the onset and slowing the progression of the 
disease process in AD transgenic mouse models should utilize treadmill running to 
precisely regulate exercise intensities and volume. 
 This study demonstrated the beneficial effects of a long-term (12-month) 
treadmill exercise training regimen in cognitive improvement and amyloid plaque 
reduction in 15-month old Tg2576 mice. Reports suggest that reducing soluble Aβ 
concentrations subsequently reduces oligomerization and plaque levels in AD mouse 
models as aging progresses. Even though physical activity has been used as an 
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intervention to reduce plaque levels and improve cognition in AD mouse models 
(Parachikova et al., 2008), the prophylactic impact of exercise training at varying 
intensities for a prolonged period in reducing amyloid plaque is not established. Moore et 
al. (2016) demonstrated dose response reduction of soluble Aβ levels in the cortex and 
hippocampus of 6-month old Tg2576 mice after 3 months of exercise training, starting at 
3 months of age. They completed the exercise training regimen prior to amyloid plaque 
development which is typically about nine months of age in Tg2576 mice. The current 
study was a follow-up to the Moore study, utilizing the same experimental design but 
with a long-term exercise training regimen. 
 For the first time, these experiments demonstrate that the intensity of exercise 
training is imperative to elicit a dose response on cognitive performance and amyloid 
plaque levels in an AD mouse model. An exercise training regimen in AD mouse models 
becomes relevant for potential exercise interventions in AD patients. Whether exercise 
training at varying intensities can be used as a preventative, treatment, or reversal 
strategy against the pathogenesis of AD needs to be investigated in human patients. The 
exercise training regimen in this study was for 12 months beginning before Aβ 
oligomerization began. In human patients, the age at which Aβ aggregation begins is 
difficult to detect. Firstly, novel techniques need to be developed to detect early levels of 
Aβ before aggregation. Lastly, a quantified exercise training regimen needs to be 
employed to elicit beneficial responses. Whether a long-term exercise training regimen 
like the one used in this study could be beneficial in human AD patients is still 
uninvestigated. In addition, the dose and duration of exercise intervention, and extent of 
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beneficial effects post exercise intervention are important questions that need to be 
addressed in the field of AD.  
 Furthermore, mechanistic pathways of physical activity in AD pathogenesis 
remain cryptic. Exercise training interventions which are quantified could shed light into 
APP processing, Aβ production, aggregation, and clearance in the brain. Understanding 
the structural and molecular characteristics of different Aβ species and its interactions 
with clearance/degradation molecules due to treadmill exercise may increase knowledge 
of potential therapeutic targets. Additionally, utilizing mouse models with mutated APP 
and altered clearance mechanisms could help define factors affecting the trafficking and 
processing of Aβ. 
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APPENDICES 
 
Appendix A: Protocols 
 
Appendix A-1. Tissue protein extraction from soleus muscles with CellLytic™ MT 
and protein quantification with Pierce™ BCA protein assay kit.  
Post isolation of left and right soleus muscle from the hind limbs of mice, the CellLytic 
kit, catalog number C 3228, from Sigma Aldrich was utilized for tissue protein 
extraction. Quantification of protein content in muscle was conducted through Pierce 
BCA protein assay kit from Thermo Fisher Scientific, catalog number 23225. 
 
Appendix A-2. NIH ImageJ analysis of amyloid plaques 
Procedure 
Mosaic images of Thioflavin-S stain 
1. Procure mosaic images at 10X magnification on a Zeiss Axio Imager M1 under 
identical exposure settings in the FITC channel 
2. Equally threshold the images using the “Threshold” feature 
3. For all representative mosaic images, set the boundaries of each individual brain 
section including the hippocampus and cortex using the mosaic function 
4. Obtain sequential images that encompasses the entire area of the tissue boundary 
(between 25 and 50 images per section) 
5. Stitch the individual images using the stitch function to produce a single image 
Single images of DAB stain 
1. Procure single images at 40X magnification on a Zeiss Axio Imager M1 under 
identical exposure settings in the brightfield channel 
2. Export the single images onto NIH ImageJ software 
3. Indicate brain regions of interest using the “Pencil” feature 
4. Quantify Aβ plaques in the cortex and hippocampus using the “Analyze Particles” 
feature 
5. Compare group means for the percentage of brain area measured 
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Appendix A-3. Open Field Test 
Procedure 
1. Place mice in the center of a white box (l38.5xw30xh30 cm) and allow to move 
freely for 10 min 
2. Using Stoelting Anymaze software, measure the distance traveled and average 
speed 
 
Appendix A-4. Morris Water Maze Test 
Procedure 
Morris Water Maze testing was conducted in a 150 cm diameter pool divided into four 
quadrants with the “goal quadrant” containing a submerged platform that the mice had to 
find. Mice had a 7 day acquisition period with four 60 second trials per day. If the animal 
did not find the platform within 60 seconds, lead it to the platform and allow to remain on 
the platform for 30 seconds. All MWM trials were evaluated using ANY-maze video 
tracking system (Stoelting Co., Wood Dale, IL). 
I. Cued Trial 
1. Conduct two days of cued trials in which a tennis ball denotes platform 
location  
2. Conduct four trials per cued day where the submerged platform is cycled 
through each quadrant 
3. Place mice in quadrant opposite to the goal quadrant in each of the trials 
and record the time, distance, and speed covered 
II. Acquisition Trial 
1. Conduct acquisition trial for five consecutive days. For each of the 
successive trails, place black shaped cues on the walls surrounding the 
pool 
2. Place the mice in a different quadrant using a random start pattern and 
record the time, distance, and speed 
III. Probe Trial 
1. Conduct a single probe trial after a one hour delay following the last 
acquisition trial. Remove the platform. 
2. Place the mice in the quadrant opposite the goal quadrant and record the 
time, distance, and speed 
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Appendix A-5. Novel Object Recognition Test 
Procedure 
Mice were first acclimated to the test area for 20 minutes one day before testing 
1. During the sample trial, place the mouse into the test arena for 10 minutes and 
expose to two identical objects 
2. After ten minutes, return the mouse to its home cage  
3. After a 50 minute delay, introduce the mouse back into the test area for 10 
minutes during the test trial with one of the objects from the sample trial and a 
novel object 
4. Record time spent investigating the objects for 10 minutes during the sample trial 
and test trial using Stoelting Anymaze software 
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Appendix B: Raw Data 
 
Appendix B-1.  Body weight raw data (All values in grams). 
Animal 
# 
Months 
Sedentary 
Group 
3 4 5 6 7 8 9 10 11 12 13 14 15 
1 17 18 20 22 23 25 26 28 28 29 31 31 33 
2 19 19 21 22 23 25 26 28 29 31 32 34 35 
3 17 18 19 20 22 22 23 24 24 26 27 30 31 
4 18 20 21 24 25 26 28 28 29 29 30 32 32 
Low 
Intensity 
Group 
             
1 19 19 22 23 25 26 26 28 28 30 32 34 35 
2 16 17 18 20 21 23 24 26 27 28 30 31 31 
3 16 17 19 21 22 24 24 26 27 28 29 29 30 
4 16 17 19 19 22 20 22 22 22 24 24 28 30 
5 18 20 19 18 18 18 21 21 21 22 25 26 29 
6 14 15 16 18 19 22 23 25 25 26 27 27 28 
7 15 16 18 20 22 22 24 26 26 27 28 30 31 
8 15 16 16 17 17 19 22 23 25 25 26 26 28 
9 18 20 21 21 25 25 26 27 28 28 29 30 32 
High 
Intensity 
Group 
             
1 14 16 18 19 19 23 26 27 27 29 31 32 34 
2 13 15 15 16 18 21 21 23 24 25 25 28 30 
3 16 15 17 20 23 25 25 24 24 27 28 31 31 
4 17 19 20 23 25 24 26 27 27 28 29 30 30 
5 15 17 18 23 23 25 26 25 27 29 31 33 33 
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Appendix B-2.  Food intake raw data (values are in grams). 
 
Animal # Food Intake 
Sedentary Group  
1 2 
2 4 
3 3 
4 3 
Low Intensity Group  
1 2 
2 2 
3 4 
4 3 
5 2 
6 4 
7 4 
8 2 
9 3 
High Intensity Group  
1 3 
2 2 
3 3 
4 2 
5 4 
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Appendix B-3. Citrate synthase activity raw data (values are in µmoles/min g wet weight). 
 
Animal # CS Activity 
Sedentary Group  
1 24.44023 
2 27.97466 
3 26.06958 
4 28 
Low Intensity Group  
1 88.79949 
2 68.84706 
3 81.92579 
4 70.06199 
5 35.19393 
6 55.61629 
7 42.82353 
8 96.07964 
9 56.73935 
High Intensity Group  
1 146.1271 
2 144.478 
3 138.4242 
4 132.1587 
5 137.4479 
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Appendix B-4.  Amyloid plaque % area. 
 
Animal # Cortex Hippocampus 
Sedentary Group   
1 0.380000 0.584000 
2 0.300000 0.393500 
3 0.467000 0.303000 
4 0.525500 0.333500 
5 0.487000 0.377000 
6 0.304000 0.446000 
Low Intensity Group   
1 0.280500 0.249000 
2 0.311000 0.205000 
3 0.258500 0.291000 
4 0.328000 0.213000 
5 0.297500 0.247000 
6 0.367000 0.221000 
High Intensity Group   
1 0.1810 0.0860 
2 0.1250 0.0000 
3 0.1165 0.0260 
4 0.1800 0.0975 
5 0.1910 0.0040 
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Appendix B-5.  Open field test raw data (distance covered in area units). 
 
Animal # Total distance Middle field distance 
Sedentary Group   
1 0.284 0.056 
2 0.154 0.013 
3 0.21 0.052 
4 0.177 0.017 
Low Intensity Group   
1 0.222 0.015 
2 0.186 0 
3 0.2 0.021 
4 0.196 0.035 
5 0.181 0.045 
6 0.176 0.051 
7 0.171 0.014 
8 0.167 0.031 
9 0.158 0.025 
High Intensity Group   
1 0.162 0.037 
2 0.157 0.013 
3 0.252 0.117 
4 0.147 0.101 
5 0.242 0.117 
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Appendix B-6.  Morris water maze acquisition phase time to platform raw data (values are 
in seconds). 
 
Animal # Day 1 Day 2 Day 3 Day 4 Day 5 
Sedentary Group 28.75 22.5 21.75 22.25 23.75 
1 58.25 49.25 45.25 37.5 36 
2 35.25 34.75 25.5 30 31.5 
3 25.75 25 24.5 20.75 24.25 
4 48 22.75 22.5 23.25 26.5 
5 54.5 60 52.25 47 39.5 
Low Intensity 
Group 
     
1 48.75 45.5 30.25 17.25 19.75 
2 50.25 60 60 51.25 60 
3 25.25 29.5 33 32 28.75 
4 24.75 16.25 19.75 7.75 18.75 
5 60 59.75 60 60 44.25 
6 48 34.5 30.25 16.5 21.25 
7 60 46.25 40 32 27 
8 17.5 15.25 9 9 13.25 
9 31.5 17 25.75 9.75 6.25 
10 28.5 27 31.5 28.5 44.75 
High Intensity 
Group 
     
1 35.25 24 23 23.75 9.75 
2 14 6.5 6.5 6.25 4.25 
3 27.75 14 12.25 6 4.5 
4 25.5 19.5 9 8.25 6.5 
5 36.5 30.75 22.25 10.75 6 
6 44.5 36.25 8 7.75 7.75 
 
 
 
 
 
 
 
 
 
 
 
 92 
 
Appendix B-7.  Morris water maze probe trial raw data. 
 
Animal # Time in target 
quadrant (s) 
Latency to 
platform (s) 
Distance 
traveled (m) 
Avg. swimming 
speed (m/s) 
Sedentary 
Group 
    
1 6 48.8 13.974 0.233 
2 4.9 39.2 7.403 0.123 
3 19.1 54 14.837 0.247 
4 7.8 60 9.67 0.161 
5 8.17 59 8.6 0.145 
6 0 60 11.4 0.133 
Low Intensity 
Group 
    
1 24.2 39.4 14.372 0.24 
2 12 45.4 11.023 0.184 
3 12.6 38.2 11.171 0.186 
4 13.8 52.6 9.029 0.151 
5 13.9 32.1 11.099 0.185 
6 4.6 60 13.065 0.218 
7 6.4 60 9.554 0.159 
8 10.63 30.9 9.002 0.159 
9 5.44 36 10.59 0.146 
10 14.9 49 7.587 0.184 
High Intensity 
Group 
    
1 41.2 5 13.138 0.219 
2 28.2 8.4 14.138 0.236 
3 22.5 5 13.642 0.227 
4 38.2 6.2 13.225 0.22 
5 20.35 7 13.645 0.236 
6 36.1 3 14.118 0.287 
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Appendix B-8.  Novel objection recognition test raw data (values are investigation times in 
seconds). 
 
Animal # Right side Left side Novel Familiar 
Sedentary Group     
1 130 132 103 111 
2 95 123 65 157 
3 10 13 67 121 
4 106 105 59 55 
5 17 15 17 27 
6 30 17 37 37 
7 184 189 83 140 
8 59 112 18 53 
9 200 175 120 126 
Low Intensity Group     
1 3 4 72 85 
2 129 217 115 135 
3 59 67 48 78 
4 12 11 52 91 
5 14 20 32 74 
6 3 7 4 6 
7 11 18 152 133 
8 190 170 165 191 
9 61 51 70 96 
10 26 34 34 46 
11 8 9 79 95 
12 25 56 24 69 
High Intensity Group     
1 167 220 153 110 
2 122 125 267 143 
3 130 158 180 112 
4 9 15 25 6 
5 101 132 83 24 
6 167 187 11 5 
7 76 67 169 38 
 
 
 
 
 
 
 
 
 94 
 
 
Appendix B-9.  Novel objection recognition test raw data (values are percent of 
investigation time). 
 
Animal # Right side Left side Novel Familiar 
Sedentary Group     
1 49.6 50.4 48.1 51.9 
2 43.6 56.4 29.2 70.8 
3 43.5 56.5 35.6 64.4 
4 50.2 49.8 51.8 48.2 
5 53.1 46.9 38.6 61.4 
6 63.8 36.2 50.0 50.0 
7 49.3 50.7 37.2 62.8 
8 34.5 65.5 25.3 74.7 
9 53.3 46.7 48.9 51.1 
Low Intensity Group     
1 42.9 57.1 45.9 54.1 
2 37.3 62.7 46.0 54.0 
3 46.8 53.2 38.1 61.9 
4 52.2 47.8 36.4 63.6 
5 41.2 58.8 30.2 69.8 
6 30 70 40.0 60.0 
7 37.9 62.1 53.3 46.7 
8 51.4 48.6 46.3 53.7 
9 54.5 45.5 42.3 57.7 
10 43.3 56.7 42.5 57.5 
11 47.1 52.9 45.4 54.6 
12 30.9 69.1 25.8 74.2 
High Intensity 
Group 
    
1 43.2 56.8 58.2 41.8 
2 49.4 50.6 65.1 34.9 
3 45.1 54.9 61.6 38.4 
4 37.5 62.5 80.6 19.4 
5 43.3 56.7 77.6 22.4 
6 47.2 52.8 68.8 31.2 
7 53.1 46.9 81.6 18.4 
 
 
 
 
 
 
 
